Ascendis Pharma A/S ADR (ASND)

Schlusskurs vom Vortag:

$135.98

Offen:

$135

24-Stunden-Volumen:

388.64K

Marktkapitalisierung:

$7.58B

Einnahmen:

$288.35M

Nettoeinkommen (Verlust:

$-521.73M

KGV:

-11.83

EPS:

-11.3176

Netto-Cashflow:

$-508.61M

1W Leistung:

-5.02%

1M Leistung:

-10.10%

6M Leistung:

+41.37%

1J Leistung:

+40.65%

1-Tages-Spanne:

$133.52

$137.32

52-Wochen-Spanne:

$83.75

$161.00

Ascendis Pharma A/S ADR Stock (ASND) Company Profile

Firmenname

Ascendis Pharma A/S ADR

Sektor

Healthcare (1211)

Branche

Biotechnology (697)

Telefon

45 70 22 22 44

Adresse

Tuborg Boulevard 5, Hellerup

Mitarbeiter

137

Twitter

Nächster Verdiensttermin

2024-05-30

Neueste SEC-Einreichungen

ASND's Discussions on Twitter

Ascendis Pharma A/S ADR Stock (ASND) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-20	Eingeleitet	Jefferies	Buy
2023-06-14	Fortgesetzt	Credit Suisse	Neutral
2023-04-05	Herabstufung	Oppenheimer	Outperform → Perform
2023-04-04	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-04-03	Herabstufung	Credit Suisse	Outperform → Neutral
2022-10-20	Eingeleitet	Goldman	Buy
2022-08-30	Fortgesetzt	Berenberg	Buy
2022-03-28	Fortgesetzt	Wedbush	Outperform
2022-03-15	Hochstufung	BofA Securities	Neutral → Buy
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-14	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-06	Eingeleitet	Cowen	Market Perform
2021-12-08	Eingeleitet	Wells Fargo	Overweight
2021-10-20	Herabstufung	BofA Securities	Buy → Neutral
2021-03-30	Herabstufung	Oppenheimer	Outperform → Perform
2021-03-11	Fortgesetzt	Stifel	Buy
2020-12-17	Eingeleitet	Berenberg	Buy
2020-09-14	Fortgesetzt	JP Morgan	Overweight
2020-03-20	Eingeleitet	Oppenheimer	Outperform
2019-10-11	Eingeleitet	Morgan Stanley	Overweight
2019-03-25	Eingeleitet	Evercore ISI	Outperform
2019-01-24	Eingeleitet	Cantor Fitzgerald	Overweight
2019-01-24	Hochstufung	Leerink Partners	Mkt Perform → Outperform
2018-06-26	Eingeleitet	Stifel	Buy
2018-04-02	Bestätigt	Leerink Partners	Mkt Perform
2017-05-11	Eingeleitet	JP Morgan	Overweight
2017-03-09	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-02-09	Eingeleitet	Credit Suisse	Outperform
2016-09-26	Eingeleitet	Wedbush	Outperform

Alle ansehen

Ascendis Pharma A/S ADR Aktie (ASND) Neueste Nachrichten

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

GlobeNewswire Inc.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks Investment Research

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

GlobeNewswire Inc.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Zacks Investment Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Zacks Investment Research

Finanzdaten der Ascendis Pharma A/S ADR-Aktie (ASND)

Ascendis Pharma A/S ADR (ASND) Umsatz 2024

Ascendis Pharma A/S ADR (ASND) Nettogewinn 2024

Ascendis Pharma A/S ADR (ASND) Free Cashflow 2024

Ascendis Pharma A/S ADR (ASND) Gewinn je Aktie 2024